Clinical Features of COVID-19 Patients
Study Details
Study Description
Brief Summary
The data were retrospectively collected during the first and the second wave of epidemic in COVID-19 patients with Severe Acute Respiratory Syndrome Coronavirus 2, at the moment of intensive care unit admission and during the in intensive care unit staying.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
At the moment of intensive care unit admission and during the in intensive care unit staying, the following data were collected: peripheral lymphocyte subsets were measured by multiple-color flow cytometry, chest computed tomography and ultrasonography scans, arterial blood gas parameters (pH, partial pressure of carbon dioxide, partial pressure of oxygen, concentration of hydrogen carbonate, base excess, and arterial oxygen saturation), and pain assessed by using numeric rating scale.
Study Design
Outcome Measures
Primary Outcome Measures
- Peripheral lymphocyte subsets [Change from date of hospitalization until the date of hospital discharge or date of death from any cause, whichever came first, assessed at 60 weeks]
Peripheral lymphocyte subsets were measured by multiple-color flow cytometry,
Secondary Outcome Measures
- Chest computed tomography [From date of hospitalization until the date of hospital discharge or date of death from any cause, whichever came first, assessed every 10 days up to 60 weeks]
A chest computed tomography performed to assess lung damage
- Chest ultrasonography [From date of hospitalization until the date of hospital discharge or date of death from any cause, whichever came first, assessed every day up to 60 weeks]
Lung ultrasound score (sum of points in all 12 regions and ranges from 0 to 36; 0 points-presence of lung sliding with A lines or one or two isolated B lines; 1 point-moderate loss of lung aeration with three or four B lines (septal rockets); 2 points-severe loss of lung aeration with five or more B lines (glass rockets); and 3 points-presence of a hypoechoic poorly defined tissue characterized by consolidation)
- Pain assessment [From date of hospitalization until the date of hospital discharge or date of death from any cause, whichever came first, assessed every day up to 60 weeks]
Pain assessed by using numeric rating scale (the 11-point numeric scale ranges from '0' representing one pain extreme [e.g. "no pain"] to '10' representing the other pain extreme [e.g. "pain as bad as you can imagine" or "worst pain imaginable])
- Upper airway damages [From date of hospitalization until the date of hospital discharge or date of death from any cause, whichever came first, assessed every day up to 60 weeks]
Macroscopic and microscopic hypopharynx and larynx damages evaluated by video-laryngoscopy and light microscopy
Eligibility Criteria
Criteria
Inclusion Criteria:
-
COVID-19 patients
-
Acute respiratory distress syndrome
-
needing of ventilatory support
Exclusion Criteria:
-
asymptomatic COVID-19 patients
-
few symptoms
-
mild symptoms
-
without needing of ventilatory support
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | San Salvatore Academic Hospital | L'Aquila | Italy | 67100 |
Sponsors and Collaborators
- San Salvatore Hospital of L'Aquila
Investigators
- Study Chair: Franco Marinangeli, MD, ASL 1 - Avezzano Sulmona L'Aquila
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 26100/21